We are building Context Therapeutics to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis.
ONWARD is clinical research studies for patients with metastatic cancer who are progesterone receptor positive (PR+). ONWARD is named after onapristone, the active pharmaceutical ingredient in our investigational medicine.
ONWARD 201: will evaluate Apristor in second line (2L) metastatic breast cancer patients who are progesterone receptor positive (PR+) and who have failed prior antiestrogen monotherapy or the combination of an antiestrogen plus a Cdk4/6 inhibitor.
ONWARD 203: will evaluate Apristor in pre-surgical treatment naive breast cancer patients alone and in combination with standard of care agents.
ONWARD 220: will evaluate Apristor in 2L/3L chemotherapy resistant uterine (endometrial) and ovarian (low grade serous, granulosa) cancer patients.